Targeting Bruton's tyrosine kinase in B cell malignancies (Q38198490)

30 August 2017

Targeting Bruton's tyrosine kinase in B cell malignancies (English)

1 reference

30 August 2017

Rudi W Hendriks

1

1 reference

30 August 2017

Saravanan Yuvaraj

series ordinal

2

1 reference

30 August 2017

Laurens P Kil

series ordinal

3

1 reference

30 August 2017

language of work or name

English

0 references

publication date

1 April 2014

1 reference

30 August 2017

Nature Reviews Cancer

1 reference

30 August 2017

14

1 reference

30 August 2017

219-232

1 reference

30 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc3702

30 August 2017

0 references

cites work

The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases

1 reference

Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia

31 March 2020

1 reference

Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man.

31 March 2020

1 reference

X-linked agammaglobulinemia: new approaches to old questions based on the identification of the defective gene.

31 March 2020

1 reference

Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice

31 March 2020

1 reference

Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes

31 March 2020

1 reference

Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells

31 March 2020

1 reference

Temporal differences in the activation of three classes of non-transmembrane protein tyrosine kinases following B-cell antigen receptor surface engagement

31 March 2020

1 reference

Defective B cell development and function in Btk-deficient mice

31 March 2020

1 reference

Transgene expression of bcl-xL permits anti-immunoglobulin (Ig)-induced proliferation in xid B cells

31 March 2020

1 reference

The pre-BCR checkpoint as a cell-autonomous proliferation switch

31 March 2020

1 reference

The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages

31 March 2020

1 reference

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

31 March 2020

1 reference

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

31 March 2020

1 reference

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

31 March 2020

1 reference

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

31 March 2020

1 reference

The Src, Syk, and Tec family kinases: distinct types of molecular switches

31 March 2020

1 reference

Structure of the PH domain and Btk motif from Bruton's tyrosine kinase: molecular explanations for X-linked agammaglobulinaemia

31 March 2020

1 reference

Regulation of Btk function by a major autophosphorylation site within the SH3 domain

31 March 2020

1 reference

Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases

31 March 2020

1 reference

Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain

31 March 2020

1 reference

Severe B cell deficiency and disrupted splenic architecture in transgenic mice expressing the E41K mutated form of Bruton's tyrosine kinase

31 March 2020

1 reference

BTKbase: the mutation database for X-linked agammaglobulinemia.

31 March 2020

1 reference

Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity.

31 March 2020

1 reference

Regulation of nucleocytoplasmic shuttling of Bruton's tyrosine kinase (Btk) through a novel SH3-dependent interaction with ankyrin repeat domain 54 (ANKRD54).

31 March 2020

1 reference

Bruton's tyrosine kinase (Btk) enhances transcriptional co-activation activity of BAM11, a Btk-associated molecule of a subunit of SWI/SNF complexes

31 March 2020

1 reference

Induction of immunoglobulin heavy-chain transcription through the transcription factor Bright requires TFII-I

31 March 2020

1 reference

Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells

31 March 2020

1 reference

MicroRNAs prevent the generation of autoreactive antibodies.

31 March 2020

1 reference

Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB.

31 March 2020

1 reference

Btk dosage determines sensitivity to B cell antigen receptor cross-linking

31 March 2020

1 reference

Correction of the X-linked immunodeficiency phenotype by transgenic expression of human Bruton tyrosine kinase under the control of the class II major histocompatibility complex Ea locus control region

31 March 2020

1 reference

Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice.

31 March 2020

1 reference

Amplification of B cell antigen receptor signaling by a Syk/ITAM positive feedback loop

31 March 2020

1 reference

CD19 as a membrane-anchored adaptor protein of B lymphocytes: costimulation of lipid and protein kinases by recruitment of Vav.

31 March 2020

1 reference

Vav3 modulates B cell receptor responses by regulating phosphoinositide 3-kinase activation

31 March 2020

1 reference

31 March 2020

1 reference

Interaction between the Btk PH domain and phosphatidylinositol-3,4,5-trisphosphate directly regulates Btk.

31 March 2020

1 reference

Transphosphorylation of Bruton's tyrosine kinase on tyrosine 551 is critical for B cell antigen receptor function

31 March 2020

1 reference

BLNK: a central linker protein in B cell activation

31 March 2020

1 reference

The B-cell antigen receptor signals through a preformed transducer module of SLP65 and CIN85

31 March 2020

1 reference

Phospholipase C-gamma2 and Vav cooperate within signaling microclusters to propagate B cell spreading in response to membrane-bound antigen

31 March 2020

1 reference

Mechanism of B-cell receptor-induced phosphorylation and activation of phospholipase C-gamma2.

31 March 2020

1 reference

BTK regulates PtdIns-4,5-P2 synthesis: importance for calcium signaling and PI3K activity.

31 March 2020

1 reference

Involvement of guanosine triphosphatases and phospholipase C-gamma2 in extracellular signal-regulated kinase, c-Jun NH2-terminal kinase, and p38 mitogen-activated protein kinase activation by the B cell antigen receptor.

31 March 2020

1 reference

IkappaB kinase beta-induced phosphorylation of CARMA1 contributes to CARMA1 Bcl10 MALT1 complex formation in B cells.

31 March 2020

1 reference

Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement

31 March 2020

1 reference

Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation

31 March 2020

1 reference

Btk regulates B cell receptor-mediated antigen processing and presentation by controlling actin cytoskeleton dynamics in B cells

31 March 2020

1 reference

Pleckstrin homology domains interact with filamentous actin

31 March 2020

1 reference

Btk-dependent Rac activation and actin rearrangement following FcepsilonRI aggregation promotes enhanced chemotactic responses of mast cells

31 March 2020

1 reference

The B cell antigen receptor controls integrin activity through Btk and PLCgamma2.

31 March 2020

1 reference

Engagement of the human pre-B cell receptor generates a lipid raft-dependent calcium signaling complex

31 March 2020

1 reference

Expression of ZAP70 in chronic lymphocytic leukaemia activates NF-κB signalling.

31 March 2020

1 reference

N-linked glycosylation selectively regulates autonomous precursor BCR function

31 March 2020

1 reference

Galectin-1 is a stromal cell ligand of the pre-B cell receptor (BCR) implicated in synapse formation between pre-B and stromal cells and in pre-BCR triggering

31 March 2020

1 reference

Interaction of murine precursor B cell receptor with stroma cells is controlled by the unique tail of lambda 5 and stroma cell-associated heparan sulfate.

31 March 2020

1 reference

The adaptor protein SLP-65 acts as a tumor suppressor that limits pre-B cell expansion.

31 March 2020

1 reference

Surrogate-light-chain silencing is not critical for the limitation of pre-B cell expansion but is for the termination of constitutive signaling

31 March 2020

1 reference

BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3.

31 March 2020

1 reference

Bruton's tyrosine kinase cooperates with the B cell linker protein SLP-65 as a tumor suppressor in Pre-B cells.

31 March 2020

1 reference

Tumor suppressor function of Bruton tyrosine kinase is independent of its catalytic activity.

31 March 2020

1 reference

Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia

31 March 2020

1 reference

Defective expression of Bruton's tyrosine kinase in acute lymphoblastic leukemia

31 March 2020

1 reference

Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells

31 March 2020

1 reference

Bruton's Tyrosine Kinase and Phospholipase Cγ2 Mediate Chemokine-Controlled B Cell Migration and Homing

31 March 2020

1 reference

Binding of beta gamma subunits of heterotrimeric G proteins to the PH domain of Bruton tyrosine kinase

31 March 2020

1 reference

The G protein G alpha12 stimulates Bruton's tyrosine kinase and a rasGAP through a conserved PH/BM domain

31 March 2020

1 reference

G Protein beta gamma subunits act on the catalytic domain to stimulate Bruton's agammaglobulinemia tyrosine kinase

31 March 2020

1 reference

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

31 March 2020

1 reference

Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

31 March 2020

1 reference

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

31 March 2020

1 reference

Integration of B cell responses through Toll-like receptors and antigen receptors

31 March 2020

1 reference

Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4.

31 March 2020

1 reference

Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk

31 March 2020

1 reference

Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response

31 March 2020

1 reference

Toll-like receptor 4-, 7-, and 8-activated myeloid cells from patients with X-linked agammaglobulinemia produce enhanced inflammatory cytokines

31 March 2020

1 reference

Bruton's tyrosine kinase mediates the synergistic signalling between TLR9 and the B cell receptor by regulating calcium and calmodulin

31 March 2020

1 reference

The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens

31 March 2020

1 reference

Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy

31 March 2020

1 reference

Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status

31 March 2020

1 reference

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia

31 March 2020

1 reference

A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi.

31 March 2020

1 reference

The role of B cell receptor stimulation in CLL pathogenesis

31 March 2020

1 reference

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

31 March 2020

1 reference

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

31 March 2020

1 reference

A mouse model for chronic lymphocytic leukemia based on expression of the SV40 large T antigen

31 March 2020

1 reference

Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing

31 March 2020

1 reference

A novel chronic lymphocytic leukemia subset expressing mutated IGHV3-7-encoded rheumatoid factor B-cell receptors that are functionally proficient

31 March 2020

1 reference

CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia

31 March 2020

1 reference

Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases

31 March 2020

1 reference

Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling

31 March 2020

1 reference

Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma.

31 March 2020

1 reference

Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma

31 March 2020

1 reference

Molecular pathogenesis of mantle cell lymphoma

31 March 2020

1 reference

Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis

31 March 2020

1 reference

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

31 March 2020

1 reference

Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells

31 March 2020

1 reference

A loss-of-function RNA interference screen for molecular targets in cancer

31 March 2020

1 reference

Oncogenic CARD11 mutations in human diffuse large B cell lymphoma

31 March 2020

1 reference

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

31 March 2020

1 reference

Oncogenically active MYD88 mutations in human lymphoma

31 March 2020

1 reference

Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response

31 March 2020

1 reference

SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma

31 March 2020

1 reference

BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.

31 March 2020

1 reference

Genetic heterogeneity of diffuse large B-cell lymphoma

31 March 2020

1 reference

SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas

31 March 2020

1 reference

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

31 March 2020

1 reference

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

31 March 2020

1 reference

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

31 March 2020

1 reference

Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma

31 March 2020

1 reference

SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia

31 March 2020

1 reference

Molecular pathogenesis of multiple myeloma and its premalignant precursor

31 March 2020

1 reference

Advances in the biology and treatment of bone disease in multiple myeloma

31 March 2020

1 reference

BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma

31 March 2020

1 reference

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

31 March 2020

1 reference

Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals.

31 March 2020

1 reference

The tec family tyrosine kinase Btk Regulates RANKL-induced osteoclast maturation

31 March 2020

1 reference

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

31 March 2020

1 reference

Triggering of toll-like receptor-4 in human multiple myeloma cells promotes proliferation and alters cell responses to immune and chemotherapy drug attack

31 March 2020

1 reference

Initial genome sequencing and analysis of multiple myeloma

31 March 2020

1 reference

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

31 March 2020

1 reference

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma

31 March 2020

1 reference

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

31 March 2020

1 reference

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

31 March 2020

1 reference

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

31 March 2020

1 reference

Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma

31 March 2020

1 reference

BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas

31 March 2020

1 reference

Self-antigen recognition by follicular lymphoma B-cell receptors

31 March 2020

1 reference

Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma.

31 March 2020

1 reference

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis

31 March 2020

1 reference

Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy

31 March 2020

1 reference

Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase.

31 March 2020

1 reference

Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis.

31 March 2020

1 reference

A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis.

31 March 2020

1 reference

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells

31 March 2020

1 reference

X-Linked Agammaglobulinemia

31 March 2020

1 reference

Bruton's tyrosine kinase is essential for human B cell tolerance

31 March 2020

1 reference

Impaired precursor B cell differentiation in Bruton's tyrosine kinase-deficient mice.

31 March 2020

1 reference

The role of Tec family kinases in the regulation of T-helper-cell differentiation

31 March 2020

1 reference

Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation

31 March 2020

1 reference

Severe B cell deficiency in mice lacking the tec kinase family members Tec and Btk.

31 March 2020

1 reference

BMX and its role in inflammation, cardiovascular disease, and cancer.

31 March 2020

1 reference

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

31 March 2020

1 reference

Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans

31 March 2020

1 reference

RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents

31 March 2020

1 reference

Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor

31 March 2020

1 reference

Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells.

31 March 2020

1 reference

12 December 2020

Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells.

1 reference

12 December 2020

B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia

1 reference

12 December 2020

Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia.

1 reference

12 December 2020

Genetic defect in human X-linked agammaglobulinemia impedes a maturational evolution of pro-B cells into a later stage of pre-B cells in the B-cell differentiation pathway

1 reference

12 December 2020

xid affects events leading to B cell cycle entry

1 reference

12 December 2020

Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma

1 reference

12 December 2020

BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation

1 reference

12 December 2020

Critical function of Bmx/Etk in ischemia-mediated arteriogenesis and angiogenesis

1 reference

12 December 2020

Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]

1 reference

12 December 2020

Expression of the X-linked agammaglobulinemia gene, btk in B-cell acute lymphoblastic leukemia.

1 reference

12 December 2020

Inactivation of Btk by insertion of lacZ reveals defects in B cell development only past the pre-B cell stage

1 reference

12 December 2020

X-linked agammaglobulinemia: report on a United States registry of 201 patients

1 reference

12 December 2020

Redistribution of Bruton's tyrosine kinase by activation of phosphatidylinositol 3-kinase and Rho-family GTPases

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC3702

1 reference

Dimensions Publication ID

30 August 2017

1029057626

0 references

Fatcat ID

release_ek5rydq26natfpxv4ixjo2244e

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ek5rydq26natfpxv4ixjo2244e

24 November 2022

mapped directly with Wikidata item

1 reference